Home>>Analytical Standards>>Orlistat-d3

Orlistat-d3 (Synonyms: (–)-Tetrahydrolipstatin-d3)

Catalog No.GC49236

An internal standard for the quantification of orlistat

Products are for research use only. Not for human use. We do not sell to patients.

Orlistat-d3 Chemical Structure

Cas No.: 1356930-46-5

Size Price Stock Qty
1 mg
$666.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor.1,2,3 It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α/β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg/ml, respectively) but does not inhibit fatty acid amide hydrolase (FAAH) or KIAA1363 (IC50s = >100 µM for both). Orlistat decreases ionomycin-induced production of the endocannabinoid 2-arachidonoyl glycerol (2-AG) in N18TG2 murine neuroblastoma cells when used at a concentration of 1 µM.4 It also inhibits fatty acid synthase (FASN; Kiapp = ~0.1 µM for the human enzyme) and the proliferation of PC3 prostate cancer cells in a concentration-dependent manner.5 Orlistat (10 mg/kg) decreases serum cholesterol levels and total body weight in a mouse model of obesity induced by a high-fat diet.6 Formulations containing orlistat have been used in the treatment of adult obesity.

1.Bisogno, T., Howell, F., Williams, G., et al.Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brainJ. Cell Biol.163(3)463-468(2003) 2.Hoover, H.S., Blankman, J.L., Niessen, S., et al.Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profilingBioorg. Med. Chem. Lett.18(22)5838-5841(2008) 3.Bustanji, Y., Issa, A., Mohammad, M., et al.Inhibition of hormone sensitive lipase and pancreatic lipase by Rosmarinus officinalis extract and selected phenolic constituentsJ. Med. Plant Res.4(21)2235-2242(2010) 4.Bisogno, T., Cascio, M.G., Saha, B., et al.Development of the first potent and specific inhibitors of endocannabinoid biosynthesisBiochim. Biophys. Acta1761(2)205-212(2006) 5.Kridel, S.J., Axelrod, F., Rozenkrantz, N., et al.Orlistat is a novel inhibitor of fatty acid synthase with antitumor activityCancer Res.64(6)2070-2075(2004) 6.Ji, W., Zhao, M., Wang, M., et al.Effects of canagliflozin on weight loss in high-fat diet-induced obese micePLoS One12(6)e0179960(2017)

Reviews

Review for Orlistat-d3

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Orlistat-d3

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.